Caris Life Sciences (CAI) Non-Current Debt (2024 - 2026)

Caris Life Sciences' Non-Current Debt history runs 3 years deep, the most recent figure standing at $381.4 million for Q1 2026.

• In Q1 2026, Non-Current Debt changed N/A year-over-year to $381.4 million; the TTM figure through Mar 2026 stood at $381.4 million (changed N/A YoY), while the FY2025 annual figure was $378.8 million, up 18.59% from the prior year.
• Non-Current Debt was $381.4 million for Q1 2026 at Caris Life Sciences, up from $378.8 million in the prior quarter.
• In the past five years, Non-Current Debt ranged from a high of $381.4 million in Q1 2026 to a low of $319.4 million in Q4 2024.
• Historically, Non-Current Debt has averaged $365.9 million across 3 years, with a median of $376.3 million in 2025.
• Biggest YoY gain for Non-Current Debt was 18.59% in 2025; the steepest drop was 18.59% in 2025.
• A 3-year view of Non-Current Debt shows it stood at $319.4 million in 2024, then gained by 18.59% to $378.8 million in 2025, then rose by 0.68% to $381.4 million in 2026.
• The last three Non-Current Debt figures came in at $381.4 million (Q1 2026), $378.8 million (Q4 2025), and $376.3 million (Q3 2025), per Business Quant data.